DOT1L Targeted Library (585 compounds)

Summary of the technology

DOT1L is an attractive target for specific malignancies, such as leukemia. Inhibitors of DOT1L could potentially be used for anticancer therapy.

Otava Research Institute

Details of the Technology Offer

Histone methyltransferases are promising epigenetic drug targets. Several drugs that inhibit histone methyltransferases have been developed for anticancer therapy. DOT1L histone H3 methyltransferase methylates lysine 79 on histone H3 (H3K79), within the globular histone domain upon which DNA is wrapped.DOT1L is an attractive target for specific malignancies, such as leukemia. Inhibitors of DOT1L could potentially be used for anticancer therapy.

OTAVAchemicals DOT1L Targeted Library (585 compounds) has been carefully designed with receptor-based approach that included docking of Drug-like Green Collection in the active site of human DOT1L (crystal structure of complex with inhibitor FED2, PDB ID 4EQZ) and filtering by score values and hydrogen bonds formed between ligand and key residues of the DOT1L active site. The library comprises drug-like compounds only.

Related Keywords

  • Biological Sciences
  • Pharmaceutical Products / Drugs
  • Biology / Biotechnology
  • Synthetic Biology
  • Protein Engineering
  • Genetic Engineering / Molecular Biology
  • Molecular design Market
  • Medical Health related
  • Therapeutic
  • drug discovery

About Otava Research Institute

Otava Institute is a global provider of one-stop integrated research solutions for business and life science. Our team includes chemists, biologists, physicists whose combined efforts contribute to the complex contract research projects for pharmaceutical, agro, cosmetic and material science industries.We are dedicated to providing clients with outstanding service in these key areas and will continue to push boundaries to remain an industry front-runner. Each day we expand our core competencies delivering of new technologies to meet all the customer’s needs.

Our location in Toronto Ontario, Canada provides our clients with the added advantage of North American IP rules and regulations and secure communication and logistics. Our Ukraine – based R&D facilities represented with the Ukrainian Laboratories, that is cooperating with leading Ukrainian research institutions and carries out research work in the format of outsourcing.

We work as a preferred partner to many of the world’s top 10 pharma firms, and hundreds of other companies, providing support with creative solutions for complex technical compound issues. Our scientific knowledge, combined with our research and manufacturing capability, enables us to support chemical processing and production without ever compromising on quality.

Our experience, dedication, and commitment to quality make us an ideal partner for discovery stage research.

Taras Maiula

Never miss an update from Taras Maiula

Create your free account to connect with Taras Maiula and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Taras

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support